Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 6, 1999, Pages 515-520

  Gangadharam, Pattisapu R J ^a   Geeta, N ^a   Hsu, Y Y ^b   Wise, D L ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Depot drug delivery; Isoniazid; Pyrazinamide

Indexed keywords

ISONIAZID; POLYGLACTIN; POLYMER; PYRAZINAMIDE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG IMPLANT; MALE; MORTALITY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION; TUBERCULOSIS;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; ANTITUBERCULAR AGENTS; BIOCOMPATIBLE MATERIALS; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG IMPLANTS; ISONIAZID; LACTIC ACID; MALE; MICE; MICE, INBRED C57BL; POLYGLYCOLIC ACID; POLYMERS; PYRAZINAMIDE; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

EID: 0032974530     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Centers for Disease Control. Approaches to improving adherence to anti-tuberculosis chemotherapy. MMWR 1993; 42: 74-75, 81.
2. World Health Organization. Tuberculosis control and research strategies for the 1990's: Memorandum from a WHO Meeting. Bull World Health Organ 1992; 70: 17-21.
3. Frieden T R, Fujiwara P L, Washko R M. Tuberculosis in New York City: Turning the tide. N Engl J Med 1995; 333: 229-233.
4. Iseman M D, Cohn D L, Sbarbaro J A. Directly Observed Treatment of tuberculosis: we can't afford not to try it. N Engl J Med 1993; 328: 576-578.
5. Tuberculosis Chemotherapy Centre, Madras. A controlled comparison of intermittent (twice-weekly) isoniazid plus streptomycin and daily isoniazid plus PAS in the domiciliary treatment of pulmonary tuberculosis. Bull World Health Organ 1964; 31: 247-271.
6. Tuberculosis Chemotherapy Centre, Madras. A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. Bull World Health Organ 1970; 43: 143-206.
7. Gangadharam P R J, Ashtekar D R, Farhi D C, Wise D L. Sustained release of isoniazid in vivo from a single biodegradable polymer. Tubercle 1991; 72: 115-122.
8. Gangadharam P R J, Kailasam S, Ashtekar D R, Wise D L. Release of isoniazid for prolonged periods from a biodegradable polymer under several in vitro, simulated in vivo conditions and in animals. J Control Release 1993; 26: 87-98.
9. Gangadharam P R J, Kailasam S, Srinivasan S, Wise D L. Experimental chemotherapy of tuberculosis using single dose treatment with isoniazid in biodegradable polymers. J Antimicrob Chemother 1994; 33: 205-271.
10. Kailasam S, Daneluzzi D, Gangadharam P R J. Maintenance of therapeutically active levels of isoniazid for prolonged periods in rabbits after a single implant of biodegradable polymer. Tubercle Lung Dis 1994; 75: 361-365.
11. Kailasam S, Wise D L, Gangadharam P R J. Bioavailability and chemotherapeutic activity of clc fazimine in vivo for prolonged periods following a single implant of a biodegradable polymer. J Antimicrob Chemother 1994; 33: 273-279.
12. Gangadharam P R J. Beige mouse model for Mycobacterium avium complex (MAC) disease. Antimicrob Agents Chemother 1995; 39: 1647-1654.
13. McCune R M, Tompsett R, McDermott W. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculosis infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 1956; 104: 763-802.
14. Gurumurthy P, Nair N G K, Faghupathi Sarma G. Methods for estimation of pyrazinamide and pyrazinoic acid in body fluids. Indian J Med Res 1980; 71: 129-134.